StreetAlpha.app
Home › Stocks › ZLAB

Zai Lab Ltd (ZLAB)

Healthcare
$23.53
▲ +0.26%
LAST CLOSE · NOV 17

Zai Lab is a Shanghai-based biopharmaceutical company that sells prescription medicines for cancer, autoimmune and infectious diseases. It last closed at $23.53 on Nov 17, up 0.26% on the day. In the past 30 days there were 3 dark pool prints totaling $7.3M, the largest $3.7M.

AI Auto Pilots
Is ZLAB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$441.7M
+0.0% vs a year ago
Net income
−$198.4M
−44.9% margin
EPS (diluted)
−$0.18
Free cash flow
−$163.3M
−37.0% margin
Balance sheet
Cash & equivalents
$549.7M
At Sep 30
Shareholder equity
$563.3M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $144.3M$144.3MFY2021FY2022: $215.0M$215.0MFY2022FY2023: $266.7M$266.7MFY2023FY2024: $399.0M$399.0MFY2024FY2025: $460.2M$460.2MFY2025

From ZLAB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated ZLAB in the past 90 days.
Average 12-month target
No price targets on ZLAB in the past 90 days.
Latest rating changes
CitigroupMaintained
Aug 7Buy$45
DateFirmActionRatingPrice target
Aug 7CitigroupMaintainedBuy$45
Loading…

Technical Analysis

ZLAB · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 1% below its 20 day and 4% below its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 46). The nearest support is the Pivot at $23.52, and the nearest resistance the 20 day average at $23.88.

Short trendNeutral
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 6.3%/day
Key levels
$29.0252 week high+23.3%
$25.50Swing high (Oct 21)+8.4%
$24.5250 day average+4.2%
$23.99Pivot R1+2.0%
$23.8820 day average+1.5%
$23.53Last close
$23.52Pivot−0.0%
$23.36100 day average−0.7%
$23.06Pivot S1−2.0%
$22.12Swing low (Oct 14)−6.0%
$21.37200 day average−9.2%
$15.9652 week low−32.2%
Indicators
RSI (14)46.30Middle of its rangeNeutral
MACD0.13Above its signal lineBullish
Stochastic32.2Middle of its rangeNeutral
ADX (14)13.5No clear trend
Williams %R-72.2Oversold below −80, overbought above −20Neutral
CCI (20)-17.2Oversold below −100, overbought above 100Neutral
Rate of change+7.2%Change over 10 sessionsBullish
ATR (14)$1.48Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for ZLAB

What happened before

See how ZLAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ZLAB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ZLAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ZLAB in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$7.3M
Largest print
$3.7M
Loading…

ZLAB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲52 buying vs 44 selling
  • ▲Shares held by funds +14.9%
  • ▲Funds holding +9
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding10394+9.6%
In funds' top 1063+100.0%
Held by funds–––
New / increased20 / 3215 / 29+18.2%
Reduced / sold out33 / 1128 / 21−10.2%
Put/call ratio0.47––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZLAB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZLAB is in one of them and how their past ZLAB trades turned out.

ZLAB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZLAB in an article yet. Here's the latest on the wider market.

About Zai Lab

Zai Lab is a biopharmaceutical company based in Shanghai that develops and sells prescription medicines. Its approved products treat conditions including ovarian cancer, generalized myasthenia gravis, glioblastoma, pneumonia and gastrointestinal stromal tumors. The products are sold across Greater China, where the company works with major medical centers and distributors. It also has a presence in the United States and a pipeline of additional candidates.

Headquarters
Shanghai